335 related articles for article (PubMed ID: 33116458)
21. Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT.
Stolz D; Hermansson E; Ouwens M; Singh B; Sharma A; Jackson D; Darken P; Marshall J; Bowen K; Müllerová H; Alcázar Navarrete B; Russell R; Han MK; Tansey-Dwyer D
Curr Med Res Opin; 2023 Oct; 39(10):1395-1405. PubMed ID: 37583267
[TBL] [Abstract][Full Text] [Related]
22. Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses.
Papi A; Virchow JC; Singh D; Kots M; Vele A; Georges G; Canonica GW
J Allergy Clin Immunol; 2021 Jul; 148(1):262-265.e2. PubMed ID: 33485959
[TBL] [Abstract][Full Text] [Related]
23. Budesonide/Glycopyrronium/Formoterol: A Review in COPD.
Heo YA
Drugs; 2021 Aug; 81(12):1411-1422. PubMed ID: 34342835
[TBL] [Abstract][Full Text] [Related]
24. Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease.
Singh D; Corradi M; Spinola M; Petruzzelli S; Papi A
NPJ Prim Care Respir Med; 2016 Jun; 26():16030. PubMed ID: 27309985
[TBL] [Abstract][Full Text] [Related]
25. Lung Deposition of Inhaled Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide in Healthy Volunteers and Asthma: The STORM Study.
Usmani OS; Baldi S; Warren S; Panni I; Girardello L; Rony F; Taylor G; DeBacker W; Georges G
J Aerosol Med Pulm Drug Deliv; 2022 Aug; 35(4):179-185. PubMed ID: 35128939
[No Abstract] [Full Text] [Related]
26. Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler
Virchow JC; Poli G; Herpich C; Kietzig C; Ehlich H; Braeutigam D; Sommerer K; Häussermann S; Mariotti F
J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):269-280. PubMed ID: 29989511
[TBL] [Abstract][Full Text] [Related]
27. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
[TBL] [Abstract][Full Text] [Related]
28. Targeting the Small Airways with Inhaled Corticosteroid/Long-Acting Beta Agonist Dry Powder Inhalers: A Functional Respiratory Imaging Study.
Watz H; Barile S; Guastalla D; Topole E; Cocconi D; Mignot B; Belmans D; Duman D; Poli G; Fabbri LM
J Aerosol Med Pulm Drug Deliv; 2021 Sep; 34(5):280-292. PubMed ID: 33944614
[No Abstract] [Full Text] [Related]
29. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
[TBL] [Abstract][Full Text] [Related]
30. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
McCormack M; Paczkowski R; Gronroos NN; Noorduyn SG; Lee L; Veeranki P; Johnson MG; Igboekwe E; Kahle-Wrobleski K; Panettieri R
Adv Ther; 2024 Mar; 41(3):1245-1261. PubMed ID: 38310193
[TBL] [Abstract][Full Text] [Related]
32. A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD.
Cazzola M; Rogliani P; Calzetta L; Ora J; Matera MG
Expert Rev Clin Pharmacol; 2022 Mar; 15(3):269-283. PubMed ID: 35475762
[TBL] [Abstract][Full Text] [Related]
33. Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study.
Singh D; Ciurlia G; Piccinno A; Muraro A; Bocchi M; Scuri M
Pulm Pharmacol Ther; 2017 Feb; 42():43-51. PubMed ID: 28065679
[TBL] [Abstract][Full Text] [Related]
34. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.
Virchow JC; Kuna P; Paggiaro P; Papi A; Singh D; Corre S; Zuccaro F; Vele A; Kots M; Georges G; Petruzzelli S; Canonica GW
Lancet; 2019 Nov; 394(10210):1737-1749. PubMed ID: 31582314
[TBL] [Abstract][Full Text] [Related]
35. Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study.
Voorham J; Baldi S; Santoro L; Kerkhof M; Contoli M; Fabbri LM; Kerstjens HAM; Luis López-Campos J; Roche N; Singh D; Vogelmeier CF; Price DB
Int J Chron Obstruct Pulmon Dis; 2020; 15():2739-2750. PubMed ID: 33149571
[TBL] [Abstract][Full Text] [Related]
36. DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach.
Singh D; Litewka D; Páramo R; Rendon A; Sayiner A; Tanni SE; Acharya S; Aggarwal B; Ismaila AS; Sharma R; Daley-Yates P
Adv Ther; 2023 Oct; 40(10):4282-4297. PubMed ID: 37382864
[TBL] [Abstract][Full Text] [Related]
37. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
[TBL] [Abstract][Full Text] [Related]
38. The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD.
Dean J; Panainte C; Khan N; Singh D
Respir Res; 2020 Dec; 21(1):323. PubMed ID: 33298062
[TBL] [Abstract][Full Text] [Related]
39. Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution.
Braido F; Corsico AG; Paleari D; Piraino A; Cavalieri L; Scichilone N
Ther Adv Respir Dis; 2022; 16():17534666211066063. PubMed ID: 35044875
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of single-inhaler extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium in patients with uncontrolled asthma in England.
Orlovic M; Magni T; Lukyanov V; Guerra I; Madoni A
Respir Med; 2022 Sep; 201():106934. PubMed ID: 35872377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
